{
    "Rank": 853,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT02886026",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "URU06"
                },
                "Organization": {
                    "OrgFullName": "University Hospital Bispebjerg and Frederiksberg",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors",
                "OfficialTitle": "Is Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors (LMD-BT) as Good as Conventional Inpatient PDD Guided Transurethral Tumor Resection in Patients With Low Grade Non-invasive (Ta) Bladder Tumors?",
                "Acronym": "LaserIII"
            },
            "StatusModule": {
                "StatusVerifiedDate": "October 2017",
                "OverallStatus": "Unknown status",
                "LastKnownStatus": "Recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "June 2016"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "December 2018",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "February 2019",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "June 21, 2016",
                "StudyFirstSubmitQCDate": "August 26, 2016",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 1, 2016",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "October 31, 2017",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "November 1, 2017",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Gregers Gautier Hermann",
                    "ResponsiblePartyInvestigatorTitle": "Consultant Urologist",
                    "ResponsiblePartyInvestigatorAffiliation": "University Hospital Bispebjerg and Frederiksberg"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "University Hospital Bispebjerg and Frederiksberg",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "This study compare the efficacy of conventional photodynamic (PDD) guided transurethral bladder tumor resection in the operating theatre with outpatient PDD guided laser destruction of bladder tumors through flexible cystoscopes.",
                "DetailedDescription": "A prospective randomized two-part clinical trial comprising patients with recurrent pTa low grade bladder tumors.\n\nStudy objectives and purpose:\n\n1st Objective: To evaluate whether small pTa bladder tumours can be removed with diode laser in an outpatient department with similar efficacy as by TUR-BT resection in the operating theatre.\n2nd Objective: To evaluate the patients experience of symptoms during laser treatment in the outpatient department (OPD) using quality of life (QOL) questionnaires (symptom evaluation) and Visual Analog Scale Score (pain evaluation).\n3rd Objective: To evaluate whether patients prefer standard transurethral bladder tumor resection (TUR-BT) in the operating theatre (OT) or laser treatment in the OPD.\n4th Objective: To evaluate the safety after laser treatment in the OPD.\n\nEfficacy:\n\n1st Endpoint: Proportion of patients with no tumor tissue in the bladder after 4 months and 12 months.\n2nd Endpoint: Visual Analog Scale Score (pain evaluation) in patients having tumor removed by laser in the OPD.\n\nGeneral urinary problems and QOL one week after the laser treatment. The Danish validated questionnaire (QLQ- BLS24) from EORTC will be used.\n\n3rd Endpoint: Patients preference for either OPD laser treatment procedure or TUR-BT in the OT as inpatient procedure.\n4th Endpoint: Character and severity of adverse events in relation to the outpatient treatment.\n\nStudy\n\nInclusion criteria:\n\nTa low grade bladder tumor recurrences\nUp to a tumor size of 1,5 cm\nUp to 6 tumors\nEligible patients for TUR-BT\n\nExclusion criteria:\n\nPatients with porphyria\nKnown hypersensitivity to Hexvix\u00ae or porfhyrins\nUse of concomitant anticoagulants as Marevan, Marcoumar, and Pradaxa\nDementia\nMacroscopic hematuria\nPregnant or breast feeding women\nExpected poor compliance estimated by the investigators\nPatients < 18 years\nPatients who do not read or understand Danish"
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Bladder Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Laser",
                        "Bladder cancer",
                        "Treatment",
                        "Outpatient",
                        "TUR-BT"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Not Applicable"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Parallel Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "248",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Inpatient TUR-BT",
                            "ArmGroupType": "Active Comparator",
                            "ArmGroupDescription": "Transurethral bladder tumor resection in operating theatre as inpatient.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Device: Bladder tumor resection using diathermia"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "laser bladder tumor destruction",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Outpatient laser mediated destruction of bladder tumors (LMD-BT)",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Device: Diode laser (980 nm) tumor destruction"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Device",
                            "InterventionName": "Bladder tumor resection using diathermia",
                            "InterventionDescription": "Conventional bladder tumor resection using diathermia",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Inpatient TUR-BT"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Device",
                            "InterventionName": "Diode laser (980 nm) tumor destruction",
                            "InterventionDescription": "Laser mediated destruction of bladder tumors (LMD-BT)",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "laser bladder tumor destruction"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Tumor recurrence histological identified in biopsy obtained during cystoscopy",
                            "PrimaryOutcomeDescription": "Numbers (%) of patients vith histological proven recurrence of bladder tumor after 4 months",
                            "PrimaryOutcomeTimeFrame": "4 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Lower urinary symptoms caused by laser treatment.",
                            "SecondaryOutcomeDescription": "Using the EORTC questionnaire QLQ-BLS24 the extent of symptoms are given on a unique score from 0-100, with 0 being no symptoms and 100 are worst symptoms. Mean and range score in the two arms will be compared statistically.",
                            "SecondaryOutcomeTimeFrame": "2 weeks"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Side effects to laser treatment.",
                            "SecondaryOutcomeDescription": "Symptoms measured by one unique score according to the Clavien-Dindo grading system. Mean and range score in the two arms will be compared statistically.",
                            "SecondaryOutcomeTimeFrame": "2 weeks"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Pain during laser treatment",
                            "SecondaryOutcomeDescription": "The patients record pain on a visual analogue scale of 0-10. Zero corresponds to no pain. Ten correspond to the worst possible pain.",
                            "SecondaryOutcomeTimeFrame": "Evaluated immediately after laser treatment"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nTa low grade bladder tumor recurrences\nUp to a tumor size of 1,5 cm\nUp to 6 tumors\nEligible patients for TUR-BT in GA\n\nExclusion Criteria:\n\nPatients with porphyria\nKnown hypersensitivity to Hexvix\u00ae or porfhyrins\nUse of concomitant anticoagulants as Marevan, Marcoumar, and Pradaxa\nDementia\nMacroscopic hematuria\nPregnant or breast feeding women\nExpected poor compliance estimated by the investigators\nPatients < 18 years\nPatients who do not read or understand Danish",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Gregers G Hermann, DM Sc",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "+45 38163536",
                            "CentralContactEMail": "gregersgautierhermann@regionh.dk"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Gregers G Hermann, DM Sc",
                            "OverallOfficialAffiliation": "Department of Urology, Frederiksberg hospital",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Urological department, Frederiksberg Hospital",
                            "LocationStatus": "Recruiting",
                            "LocationCity": "Copenhagen",
                            "LocationZip": "2000",
                            "LocationCountry": "Denmark",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Gregers G Hermann, MD",
                                        "LocationContactRole": "Contact",
                                        "LocationContactPhone": "+ 45 38163536",
                                        "LocationContactEMail": "gregers.gautier.hermann@regionh.dk"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001749",
                            "ConditionMeshTerm": "Urinary Bladder Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000014571",
                            "ConditionAncestorTerm": "Urologic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000052776",
                            "ConditionAncestorTerm": "Female Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005261",
                            "ConditionAncestorTerm": "Female Urogenital Diseases and Pregnancy Complications"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000001745",
                            "ConditionAncestorTerm": "Urinary Bladder Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000014570",
                            "ConditionAncestorTerm": "Urologic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000052801",
                            "ConditionAncestorTerm": "Male Urogenital Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4720",
                            "ConditionBrowseLeafName": "Urinary Bladder Neoplasms",
                            "ConditionBrowseLeafAsFound": "Bladder Tumors",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M17010",
                            "ConditionBrowseLeafName": "Urologic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26783",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M13817",
                            "ConditionBrowseLeafName": "Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8089",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases and Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4716",
                            "ConditionBrowseLeafName": "Urinary Bladder Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17009",
                            "ConditionBrowseLeafName": "Urologic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26785",
                            "ConditionBrowseLeafName": "Male Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            }
        }
    }
}